To exemplify theirutility, a SARS-CoV-2 proteome microarray containing 966 tiled 15-merpeptides was developed to profile the B-cell epitope landscape ofSARS-CoV-2 IgM and IgG antibodies in early COVID-19 infection.142 Others constructed a SARS-CoV-2 protein arraycontaining 18 purified viral proteins to detect the IgG and IgM antibodyresponses.143 In addition, antibody profilesof COVID-19 patients and prepandemic controls were analyzed usingimmunoprecipitation and sequencing (PhIP-Seq). The gene discussed is CD40LG; the disease is COVID-19.